A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...